-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Acorda Therapeutics, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2013 to Q1 2023.
- Acorda Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was -$2.04M, a 890% decline year-over-year.
- Acorda Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$43.2M, a 241% decline from 2022.
- Acorda Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $30.7M.
- Acorda Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$5.19M, a 211% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)